SCHEMBL4849408

SCHEMBL4849408

Brc1cn(Cc2cccnc2)c2cnccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.53
KCNH2 Q12809 1/20 0.53
KDM4C Q9H3R0 1/20 0.50
APP P05067 3/20 0.45
SNCA P37840 3/20 0.45
CDK2 P24941 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
CYP11B1 P15538 1/20 0.45
NFATC1 O95644 1/20 0.45
GSK3B P49841 1/20 0.45
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
CHRM1 P11229 1/20 0.44
SRC P12931 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
CYP1B1 Q16678 1/20 0.42
HTR2C P28335 1/20 0.41
ADRA1D P25100 1/20 0.41
GUSB P08236 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4857531 0.90 DYRK1A (0.66) DYRK1AKCNH2KDM4CCDK2DYRK1B
SCHEMBL29801631 0.90 DYRK1A (0.66) DYRK1AKCNH2KDM4CCDK2DYRK1B
SCHEMBL4859078 0.82 DYRK1A (0.51) DYRK1AKCNH2KDM4CCDK2DYRK1B
SCHEMBL4849658 0.81 DYRK1A (0.67) DYRK1AKCNH2KDM4CCDK2DYRK1B
SCHEMBL4847918 0.80 DYRK1A (0.52) DYRK1AKCNH2KDM4CCDK2DYRK1B
SCHEMBL4851322 0.79 LPO (0.47) DYRK1AKCNH2KDM4CCDK2DYRK1B
SCHEMBL4857588 0.79 CYP19A1 (0.50) DYRK1AKCNH2KDM4CCDK2DYRK1B
SCHEMBL4856748 0.79 DYRK1A (0.48) DYRK1AKCNH2KDM4CCDK2DYRK1B
SCHEMBL4856398 0.78 CYP11B1 (0.53) DYRK1AKCNH2KDM4CCYP11B1NFATC1
SCHEMBL4857328 0.78 CYP1B1 (0.42) DYRK1AKCNH2KDM4CCDK2DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 DYRK1A 1117/4885KCNH2 2535/4885KDM4C 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.